This assignment delves into the workings of Tresiba, a long-acting insulin analogue developed by Novo Nordisk for treating both Type 1 and Type 2 Diabetes. It explains how Tresiba regulates blood sugar levels through binding to the insulin receptor and activating specific signaling pathways. The document also outlines the side effects associated with Tresiba and emphasizes its careful administration.